Highlights in Chronic Lymphocytic Leukemia From ASH 2020 Highlights in Chronic Lymphocytic Leukemia From ASH 2020
Dr William Wierda from MD Anderson reviews key studies on chronic lymphocytic leukemia therapies from ASH 2020, including the phase 3 UNITY trial, next-generation BTK inhibitors, and CAR-T therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news
On the Horizon: Asciminib, a New Drug for Treating R/R CML On the Horizon: Asciminib, a New Drug for Treating R/R CML
A first-in-class STAMP inhibitor, asciminib, shows better efficacy than bosutinib in patients with relapsed/refractory chronic myeloid leukemia in the chronic phase.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New analysis method for predicting the risks and effects of immunotherapy
(Uppsala University) In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news
New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with IMBRUVICA® remai...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia
Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“These results reinforce the long-term value of fixed-duration,...
Source: Roche Media News - December 5, 2020 Category: Pharmaceuticals Source Type: news
Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia
Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“These results reinforce the long-term value of fixed-duration,...
Source: Roche Investor Update - December 5, 2020 Category: Pharmaceuticals Source Type: news
Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized to discont...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the Company has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 1, 2020 Category: Drugs & Pharmacology Source Type: news
Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes
In patients with chronic myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is safe and associated with better patient-reported outcomes, a nonrandomized trial reveals.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers
Risk factors for keratinocyte carcinomas were associated with the risk of developing non-Hodgkin lymphomas and chronic lymphocytic leukemia in an analysis of 92,097 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Are We Close to Predicting Treatment-Free Remission in CML? Are We Close to Predicting Treatment-Free Remission in CML?
Chronic myeloid leukemia expert Dr Richard Stone discusses the promise and clinical feasibility of two recently proposed predictive scores.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Renal Function Decline With TKI Use in Chronic Myeloid Leukaemia Renal Function Decline With TKI Use in Chronic Myeloid Leukaemia
Tyrosine kinase inhibitors are associated with renal function decline in patients with chronic myeloid leukaemia according to results of a 10-year follow up.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneous for...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem.
Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints.
Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Anticancer compounds for B cell cancer therapy targeting cellular stress response
(The Wistar Institute) Wistar and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2020 Category: Biology Source Type: news
